Scarica l'app Stockscreener
7.96
3.65%
0.28
Dopo l'orario di chiusura:
8.10
0.14
+1.76%
Precedente Chiudi:
$7.68
Aprire:
$7.86
Volume 24 ore:
4.65M
Relative Volume:
1.49
Capitalizzazione di mercato:
$1.00B
Reddito:
$631.73M
Utile/perdita netta:
$-239.78M
Rapporto P/E:
-3.9406
EPS:
-2.02
Flusso di cassa netto:
$-33.45M
1 W Prestazione:
-2.45%
1M Prestazione:
-23.39%
6M Prestazione:
-47.42%
1 anno Prestazione:
-71.37%
Intervallo 1D:
$7.735
$8.01
Intervallo di 1 settimana:
$7.25
$8.22
Portata 52W:
$6.78
$29.37
10 X Genomics Inc Stock (TXG) Company Profile
Nome
10 X Genomics Inc
Settore
Industria
Telefono
(925) 401-7300
Indirizzo
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Confronta TXG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
7.96 | 1.00B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
215.78 | 36.24B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
52.40 | 9.99B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
43.23 | 7.43B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
83.45 | 7.23B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
35.45 | 6.36B | 906.14M | -52.62M | 89.62M | -0.3621 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-13 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | Iniziato | Leerink Partners | Outperform |
| 2024-07-22 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-07-18 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-10 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-06-27 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-05-01 | Downgrade | TD Cowen | Buy → Hold |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-10 | Iniziato | Barclays | Overweight |
| 2023-03-31 | Iniziato | Stephens | Overweight |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-08-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-07-25 | Iniziato | Canaccord Genuity | Buy |
| 2022-07-15 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-07-15 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-09-14 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-15 | Iniziato | William Blair | Outperform |
| 2020-12-02 | Iniziato | Goldman | Neutral |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-10 | Iniziato | Stifel | Buy |
| 2020-03-05 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-10-07 | Iniziato | BofA/Merrill | Buy |
| 2019-10-07 | Iniziato | Cowen | Outperform |
| 2019-10-07 | Iniziato | JP Morgan | Overweight |
| 2019-09-24 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
10 X Genomics Inc Borsa (TXG) Ultime notizie
Advancing the Future of Biomarker-Driven Immunotherapy - Fierce Biotech
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis (PR Newswire) - Aktiellt
10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025 - BioSpace
BofA Securities Cuts Price Target on 10x Genomics to $12 From $16, Neutral Rating Maintained - marketscreener.com
10x Genomics (TXG) Price Target Reduced Amid Policy and Economic Concerns | TXG Stock News - GuruFocus
Biotech Leader 10x Genomics Announces Q1 2025 Earnings Date: What to Watch - Stock Titan
Positive Sentiment Still Eludes 10x Genomics, Inc. (NASDAQ:TXG) Following 29% Share Price Slump - simplywall.st
Spatial Genomics Transcriptomics Market Is Booming Worldwide | - openPR.com
Single-cell Omics Emerging Technologies and Markets Report - GlobeNewswire
Single-cell Omics Emerging Technologies and Markets Report 2025: 10x Genomics, Thermo Fisher & Illumina Lead $9.1 Billion Single-cell Omics Market by 2029 - Yahoo Finance
PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know - Yahoo Finance
10x Genomics Reports Third Quarter 2023 Financial Results - Seeking Alpha
10X Genomics stock hits 52-week low at $7.43 amid market challenges - Investing.com Canada
10X Genomics stock hits 52-week low at $7.43 amid market challenges By Investing.com - Investing.com South Africa
10 Promising Biotech Stocks to Invest in (April 2025) - Securities.io
IQ EQ FUND MANAGEMENT IRELAND Ltd Boosts Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10X Genomics stock plunges to 52-week low of $9.27 By Investing.com - Investing.com South Africa
10X Genomics stock plunges to 52-week low of $9.27 - Investing.com
We Think 10x Genomics (NASDAQ:TXG) Can Easily Afford To Drive Business Growth - Yahoo Finance
UPC infringement case can resume after EPO upholds 10x Genomics patent - JUVE Patent
10x Genomics Comments on Second UPC Preliminary Injunction Decis - GuruFocus.com
10x Genomics: Lower Cost Innovation May Drive A Rebound - Seeking Alpha
These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company
Long Read Sequencing Market Top Companies Study10X Genomics, - openPR
2 Reasons to Sell TXG and 1 Stock to Buy Instead - Yahoo Finance
Bruker motion backfires in US patent dispute with 10x Genomics, Harvard - MLex
Press Release Distribution & PR Platform - ACCESS Newswire
10x Genomics IncOrdinary SharesClass A to Host Earnings Call - ACCESS Newswire
10x Genomics’ (TXG) Sell (E+) Rating Reiterated at Weiss Ratings - Defense World
Citigroup Issues Pessimistic Forecast for 10x Genomics (NASDAQ:TXG) Stock Price - Defense World
Strategic Move: Healthcare Giant Zimmer Biomet Taps Communications Veteran from 10x Genomics - Stock Titan
10x Genomics gets injunction against Parse Biosciences' ATAC Products - MSN
10x Genomics Dodges Appeal In DNA Analysis Patent Clash - Law 360 UK
10x genomics CEO Serge Saxonov sells $84,393 in stock By Investing.com - Investing.com Australia
Rhumbline Advisers Sells 1,641 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
10x genomics CEO Serge Saxonov sells $84,393 in stock - Investing.com
Sanctuary Advisors LLC Purchases 6,474 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
Short Interest in 10x Genomics, Inc. (NASDAQ:TXG) Expands By 34.4% - Defense World
10x Genomics Secures Injunction Against Parse Biosciences' Plann - GuruFocus.com
10x Genomics Secures Injunction Against Parse Biosciences’ Planned ATAC Products - The Malaysian Reserve
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products - Marketscreener.com
10x Genomics secures injunction against Parse Biosciences - Investing.com
10x Genomics gets injunction against Parse Biosciences' ATAC Products (TXG:NASDAQ) - Seeking Alpha
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products – Company Announcement - Financial Times
ARK Investment Management LLC Purchases 1,193,712 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
SVB Wealth LLC Acquires Shares of 522,609 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
Ieq Capital LLC Purchases 50,722 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
ING Groep NV Acquires New Shares in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics, Inc. (NASDAQ:TXG) CEO Sells $56,368.44 in Stock - MarketBeat
Director of 10x Genomics Picks Up 184% More Stock - Simply Wall St
Oxford Nanopore Expands Compatibility With 10x Genomics To Unlock Deeper Insights in Single-Cell Transcriptomics - Technology Networks
10 X Genomics Inc Azioni (TXG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.29%
0.76%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):